Cannabis companies have been pushing the envelope of acceptable marketing and business practices by insinuating unproven benefits for their products while also looking to create the strongest goods possible
The Brazilian Superior Court of Justice recently legalised hemp with up to 0.3% THC for medicinal and industrial purposes. This short report analyses this new ruling in detail
As the 68th session of the United Nations (UN) Commission on Narcotic Drugs approaches in March 2025, the international debate over the regulation of hexahydrocannabinol (HHC) continues to gain momentum
Rescheduling of cannabis in the US will headline a somewhat slow slate of regulatory changes in 2025, CannIntelligence predicts, while much of the remaining positivity for cannabis revolves around the status quo being maintained
On the surface, 2024 could seem like a disappointing year for commercial cannabinoids, but scratch the surface and it really was not all that bad
Join the Tamarind Intelligence leadership team for a compelling round-table discussion with four top industry experts. They’ll reflect on the major moments of 2024 in the reduced-risk nicotine world and share their insights for 2025.
This report offers a detailed analysis of the current regulatory framework in place in Spain for hemp, CBD and other cannabinoids, as well medical and recreational cannabis
The ever-changing make-up of US president-elect Donald Trump’s nominees for posts in his administration – still far from set in stone – offers a few new options that will impact on cannabis and hemp
Cannabis may help sleep, according to Australian researchers who found evidence of the hypnotic properties of cannabinol (CBN) and say their study is the first to use objective measures to prove CBN increases sleep
Rupert Wilson, managing director at Strategic Business Consulting and former Rothmans International tobacco expert, sits down with Tamarind Intelligence’s Tim Phillips to examine the influence of novel nicotine products on the performance and strategic direction of public tobacco firms.
President Petr Pavel recently signed into law an amendment to the Act on Addictive Substances that regulates “psychomodulating substances”. This short report analyses this new law in detail
This report examines the models of recreational cannabis legalisation that are currently being implemented in Europe, their nuances, and the commercial opportunities they may provide
Join Tamarind Intelligence founder Tim Phillips and Editorial Director Barnaby Page as they explore the complexities of the illicit e-cigarette trade.
Brazilian pharmaceutical company Ease Labs officially announced the acquisition this month of Plena, a cannabis cultivation and extraction company based in Colombia
Clinical trials on CBD-based medical drug Epidiolex missed their main goal of registering a significant reduction in the frequency of seizures experienced by patients in Japan, based on the results reported by manufacturer Jazz Pharmaceuticals
Republican nominee for vice-president JD Vance has been silent on vaping, tobacco alternatives and the Ohio cannabis legalisation debate, but some of his comments suggest he may support the regulation of recreational cannabis
Executives were taken aback by the enthusiasm vendors showed for a nicotine vape brand in Dubai with a US West Coast theme, even though it involves a product that the UAE only recently legalised
The proposed and withdrawn amendment to ban CBD products in Italy has reappeared as part of a bill aimed at enhancing public safety and combating crime
CannIntelligence presents the latest regulatory and market developments and trends in the global cannabis industry in slide deck format. The slide deck covers the latest developments from the second quarter of 2024